Purpose: The aim of this study was to assess the efficacy and safety of ranibizumab in patients with diabetic macular edema (DME). Methods: We conducted a retrospective analysis of consecutive patients with vision loss due to DME who were treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as-needed basis. The primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and the number of intravitreal injections (IVI) at 12 months. Results: One hundred and six eyes of 78 patients were included. BCVA changed from 48.3 (20/100) letters at baseline to 59.0 letters (20/63) at 12 months (p < 0.0001; mean gain: +10.7 letters), and 38% of the patients had a final BCVA >70 letters. CRT decreased from 519 µm at baseline to 355 µm at 12 months (p < 0.0001). The threshold of the first quartile of the baseline VA was 40 letters. Patients with a baseline VA >40 letters had a higher final VA of 66 ± 14 letters (20/50) versus 43 ± 18 letters (20/125) for patients with a baseline VA ≤40 letters (p < 0.0001). A mean number of 5.4 (3-10) IVI were administered. Conclusion: This study conducted in a clinical setting confirms the results of previous randomized trials. The final BCVA was mainly influenced by the baseline BCVA, which supports the utility of early DME treatment before patients experience a severe vision loss.

Keywords:
Diabetic macular edema, Ranibizumab, Anti-vascular endothelial growth factor, Retinal diseases, Real-life study
1.
Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564.
2.
Delcourt C, Massin P, Rosilio M: Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population. Diabetes Metab 2009;35:431-438.
3.
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
4.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
5.
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
6.
Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS; RIDE and RISE Research Group: Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 2015;122:2504-2513.e1.
7.
Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-1203.
8.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
9.
European public assessment report (EPAR) for Lucentis. lucentis_pic_reev_avis2_modifiele13022015_ct13967(1).pdf.
10.
Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al: Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-756.e4.
11.
Souied EH, Oubraham H, Mimoun G, Cohen SY, Quere S, Derveloy A, et al: Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The TWIN Study. Retina Phila Pa 2015;35:1743-1749.
12.
Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, et al: Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409-413.
13.
Cohen S-Y, Souied EH, Weber M, Dupeyron G, de Pouvourville G, Lievre M, et al: Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. Graefes Arch Clin Exp Ophthalmol 2011;249:521-527.
14.
Ziemssen F, Eter N, Fauser S, Bopp S, Radermacher M, Hasanbasic Z, et al: Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany (in German). Ophthalmologe 2015;112:246-254.
15.
Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al: Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol 2013;97:1161-1167.
16.
Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P, et al: New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 2012;26:485-493.
17.
Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al: Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-756.e4.
18.
Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, et al: Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016;100:787-795.
19.
Ghanchi F, Hazel CA: South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. Eye Lond Engl 2016;30:133-138.
20.
Dugel PU, Hillenkamp J, Sivaprasad S, Vögeler J, Mousseau M-C, Wenzel A, et al: Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Ophthalmol 2016;10:1103-1110.
21.
Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-381.
22.
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
23.
Stéphan S, Fajnkuchen F, Addou-Regnard M, Grenet T, Nghiem-Buffet S, Chaine G, et al: Severity of diabetic macular edema (DME) in Seine St Denis among patients treated by anti-VEGF (in French). J Fr Ophtalmol 2014;37:717-721.
24.
Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I: The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology 2016;123:1581-1587.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.